Masitinib - AB Science
Alternative Names: AB-07105; AB-1010; Alsitek; Masican; Masipro; Masitinib mesilate; Masitinib mesylate; MasivieraLatest Information Update: 11 Jul 2024
At a glance
- Originator AB Science
- Class Anti-inflammatories; Antiasthmatics; Antidementias; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antirheumatics; Antivirals; Benzamides; Mood stabilisers; Nootropics; Piperazines; Pyridines; Small molecules; Thiazoles; Vascular disorder therapies
- Mechanism of Action Angiogenesis inhibitors; Colony stimulating factor inhibitors; Coronavirus 3C-like proteinase inhibitors; Endopeptidase Clp inhibitors; Focal adhesion protein-tyrosine kinase inhibitors; Lyn protein-tyrosine kinase inhibitors; Macrophage colony-stimulating factor receptor modulators; Mast cell inhibitors; Platelet-derived growth factor receptor antagonists; Protein tyrosine kinase inhibitors; Proto oncogene protein c-kit inhibitors; Proto-oncogene protein c-fyn modulators; Type 3 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preregistration Amyotrophic lateral sclerosis
- Phase III Alzheimer's disease; Asthma; Colorectal cancer; Gastrointestinal stromal tumours; Mastocytosis; Multiple myeloma; Multiple sclerosis; Pancreatic cancer; Peripheral T-cell lymphoma; Prostate cancer
- Phase II/III Crohn's disease; Ovarian cancer
- Phase II Breast cancer; Chronic obstructive pulmonary disease; COVID 2019 infections; Head and neck cancer; Non-small cell lung cancer; Parkinson's disease
- Phase I/II Gastric cancer; Glioblastoma; Liver cancer; Oesophageal cancer
- No development reported Psoriasis; Stroke
- Discontinued Malignant melanoma; Mood disorders; Progressive supranuclear palsy; Rheumatoid arthritis
Most Recent Events
- 08 Jul 2024 Efficacy and adverse events data from phase II AB20001 trial in COVID-2019 infections released by AB Science
- 29 May 2024 AB Science expects formal opinion from CHMP on marketing authorisation application of masitinib for Amyotrophic lateral sclerosis in June 2024
- 29 May 2024 The CHMP adopts trending toward negative opinion on MAA for Amyotrophic lateral sclerosis